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Background. Eczema herpeticum (EH) is a potentially serious, systemic complication in subjects with atopic dermatitis (AD)
caused by herpes simplex virus (HSV). The innate immune dysregulation that predisposes these subjects to cutaneous viral
infections is not well understood. We tested the hypothesis that defects in mannan-binding lectin (MBL) may be associated with
an increased risk of EH. Methods. We evaluated serum MBL levels and functional activity in 13AD subjects with a history of
EH (EH+) and 21AD subjects with no history of EH (EH−). MBL levels were detected by enzyme immunoassay. MBL pathway
functional activity was evaluated by determining MBL C4b deposition capacity. Results. We found no statistical diﬀerence in MBL
serum levels or function between EH+ and EH− groups. Conclusion. Considering the limitations of this study (e.g., small samples
size) our ﬁndings suggest that MBL defects do not play a role in EH.
1.Introduction
Atopicdermatitis(AD)isthemostcommonchronic,inﬂam-
matory skin disease. Although rare, one of the most severe
complications of AD is a widely disseminated cutaneous
infection with HSV, called eczema herpeticum (EH) [1].
Episodes of EH can be complicated by keratoconjunctivitis
and viremia, leading to multiple organ involvement includ-
ing meningitis and encephalitis. This makes EH one of the
few true emergencies in dermatology [2].
Recently, it has been shown that AD subjects with a
history of EH have a more severe phenotype as compared
to AD subjects without a history of this viral complication.
ADEH+ patients have greater disease severity index score,
greater allergen sensitization, and higher total IgE levels and
peripheral eosinophilia [3].
The major hypothesis put forth to explain AD subjects’
susceptibility to HSV and other viral infections is that
they have one or more defects in the innate immune
system. Thus far, the speciﬁc mechanism responsible for this
condition has not been determined. Numerous publications
have documented that the epidermis of AD subjects has
reduced expression of antimicrobial proteins. Howell et al.
[4] found that the LL-37-deﬁcient (Clnp−/−)m i c eh a d
greater HSV replication on the skin surface than wild-type
mice, suggesting that the lack of this antimicrobial peptide
may provide an explanation for AD patients’ predisposition
to EH. Another hypothesis contends that the impaired
recruitment and function of plasmacytoid dendritic cells
(PDC), which produce antiviral type 1 interferons, would
predispose AD subjects to viral skin infections [1]. Recently,
we have also highlighted that the greater viral susceptibility
may be related to a defect in epidermal tight junctions which
is observed in AD subjects [5].
There is preliminary epidemiologic evidence to sug-
gest that Mannan-Binding Lectin (MBL) is important for2 Dermatology Research and Practice
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Figure 1: Mannan-binding lectin levels and activity in atopic dermatitis patients with and without a history of eczema herpeticum are not
diﬀerent. (a) Serum levels of MBL (ng/mL; ref. range > 200ng/mL) and (b) MBL functional activity (lectin units; ref. range > 0.2l e c t i n
units) in ADEH+ (n = 13) or ADEH− (n = 21) patients. Red line represents lower limit of the normal reference range.
clearance of several common viruses (hepatitis B, HIV, and
inﬂuenza A) [6]. In this study we tested the hypothesis that
defects in MBL level or activity may be associated with an
increased risk for EH.
MBL, a soluble molecule from the collectin family of
pathogen-related receptors, is a C-type lectin of hepatic
origin that binds and circulates in a complex with MBL-
associated serine proteases (MASPs). MBL-MASP2 initiates
complement activation and microbial opsonization resulting
in phagocytosis of foreign pathogens.
The expression of functional MBL protein is largely
genetically determined [7]. Serum MBL deﬁciency has been
observedin10to15%ofCaucasianswithsigniﬁcantlyhigher
p e r c e n t a g e sr e p o r t e di ns u b j e c t so fA f r i c a no rS o u t hA m e r i -
can Indian descent [6]. Such deﬁciencies and their variant
alleles have been associated with increased susceptibility to
bacterialinfectionsinneutropenicsubjects,poorerprognosis
in cystic ﬁbrosis patients, or more severe meningococcal
disease [6].
Interestingly, Sepp¨ anen et al. [8] demonstrated an MBL2
(MBL gene) structural variant genotype (A/O or O/O) that
wasmorecommonamongthepatientswithrecurrentHSV-2
infectioncomparedwithhealthycontrolsorcontrolspositive
for HSV-2 antibodies. A recent report highlights a clear
association between extremely low MBL levels and the BB
MBL haplotype in several members of a Turkish family
who also suﬀered from recurrent staphylococcal infections
(skin, ear, and airway) and a pruritic, eczematous dermatitis
[9]. Two genetic studies have reported conﬂicting results
regarding MBL polymorphisms and their associations with
AD. Brandrup et al. [9] did not ﬁnd an association between
the MBL B allele and AD susceptibility in a Japanese
population. In contrast, a study of Brazilian AD subjects
demonstrated that the three exon 1 variants (B, C, and D)
were observed more frequently than in a healthy control
population [10].
NostudieshaveevaluatedMBLlevelsorgenotypesinAD
EH+ subjects.
2.MaterialsandMethods
2.1. Study Population. This study received approval from the
Johns Hopkins Medical Institution IRB as well as by the
ethics committee of the Department of Dermatology and
Allergy, Ludwig Maximilian University, Munich, Germany.
Writteninformedconsentwasobtained.Serumwascollected
from adult subjects whose diagnosis of AD was made by a
dermatologist who specializes in the care of AD (LAB and
AW; n = 34). AD subjects were categorized as EH+ if the
subject had an episode of EH that was observed by one of the
two dermatologists and for which the presence of HSV was
conﬁrmed by one of the following means (culture, Tzanck
smear, PCR, or immunoﬂuorescence assay). Subjects in the
control AD group were selected if they had no history of EH
as assessed by a careful history (EH−) and had never been
prescribed systemic antiviral therapy.
2.2. MBL Serum Levels and Functional Assay. Serum MBL
levels were detected by enzyme immunoassay using mono-
clonal antibody against the oligomeric MBL carbohydrate-
binding domain. MBL pathway functional activity was
evaluated indirectly by determining MBL C4b deposition
capacity with an anti-human C4 monoclonal antibody. Both
of these studies were performed at IBT reference laboratory
(Lenexa, Kansas).
2.3. Statistical Analysis. Diﬀerences between groups were
evaluated using a 2-tailed, unpaired t-test. A P value of
≤ 0.05 was considered statistically signiﬁcant. Data were
expressed as mean ± SEM.
3. Results and Discussion
The EH− cohort (n = 21) had a mean age of 30 ± 4y e a r s
and 16 of 21 subjects (76%) were female, whereas the EH+
cohort (n = 13) had a mean age of 36 ± 5y e a r sa n d4o f1 3Dermatology Research and Practice 3
subjects (31%) were female. The mean serum MBL level (ref.
range > 200ng/mL) for EH− patients was 1727±323ng/mL
and for EH+ patients was 1549 ± 346ng/mL (P = 0.703)
(Figure 1(a)). MBL functional activity as measured by C4b
deposition assay (ref. range > 0.2l e c t i nu n i t s )f o rE H −
patients was 0.6 ± 0.1 lectin units and for EH+ patients was
0.7±0.1 lectin units (P = 0.685) (Figure 1(b)). There was no
statistically signiﬁcant diﬀerence in MBL levels or functional
activity between the two AD groups (EH− and EH+).
Our study demonstrates that AD subjects with a history
of EH had similar levels and functional activity of serum
MBLasADsubjectswithnohistoryofEH.Thissuggeststhat
MBL deﬁciency or defects in this pathway are not likely to be
a susceptibility factor for the development of EH. Evaluation
of this in a larger cohort of AD patients, as well as in ADEH+
subjects during an acute EH event, would be needed to
solidify this conclusion.
4. Conclusions
Clinical studies aiming to clarify the pathogenesis of EH in
AD are limited by the low prevalence of the disease and often
by the very young age of patients involved. Additionally, a
clinical test that can carefully characterize the subphenotype
after the acute event is not available, thus making it diﬃcult
to study very well-characterized populations. Considering
these limitations, we believe that any data, even negative,
should be made available to other investigators in the
ﬁeld. Further work is needed to determine the precise
defect(s) that predispose AD patients to this potentially life-
threatening viral skin infection.
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